An Assessment of the In Vivo Biological Effects of Diethyldithiocarbamate (DTC) in HIV-Infected Patients
Status:
Completed
Trial end date:
1996-09-01
Target enrollment:
Participant gender:
Summary
To determine, in HIV-infected patients, the magnitude and duration of the biological effects
of ditiocarb sodium (sodium diethyldithiocarbamate; DTC) that may be relevant to treatment of
HIV infection.
DTC has been studied in previous clinical trials in HIV-infected patients with the suggestion
of delay in disease progression to AIDS and improvement in CD4 counts while on the drug.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)